Condition: Non-Small Cell Lung Cancer · Sponsor: AbbVie
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer. Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug) + chemotherapy, budigalimab +chemotherapy, or pembrolizumab +chemotherapy. In Stage 2, there are 2 treatments arms. Participants will either receive livmoniplimab (optimized dose) in combination with budigalimab +chemotherapy or placebo in combination with pembrolizumab +chemotherapy. Chemotherapy consists of IV Infused pemetrexed + IV infused cisplatin or IV infused or injected carboplatin. Approximately 840 adult participants will be enrolled in the study across 200 sites worldwide. Stage 1: In cohort 1, participants will receive intravenously (IV) infused livmoniplimab (dose A)+ IV infused budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + IV Infused pemetrexed. In cohort 2, participants will receive livmoniplimab (dose B) + bud…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Moores Cancer Center /ID# 267782 | La Jolla, California, United States | Recruiting |
| Memorial Hospital West /ID# 262221 | Pembroke Pines, Florida, United States | Recruiting |
| Bond Clinic /ID# 262611 | Winter Haven, Florida, United States | Recruiting |
| University Cancer & Blood Cent /ID# 261824 | Athens, Georgia, United States | Recruiting |
| The University of Chicago Medical Center /ID# 262259 | Chicago, Illinois, United States | Recruiting |
| University of Kansas Medical Center /ID# 263196 | Westwood, Kansas, United States | Recruiting |
| Baptist Health Lexington /ID# 261823 | Lexington, Kentucky, United States | Recruiting |
| Cancer & Hematology Centers of Western Michigan - East /ID# 261826 | Grand Rapids, Michigan, United States | Recruiting |
| Washington University-School of Medicine /ID# 262759 | St Louis, Missouri, United States | Recruiting |
| Stony Brook Cancer Center /ID# 261954 | Stony Brook, New York, United States | Recruiting |
| Cone Health Cancer Center /ID# 262583 | Greensboro, North Carolina, United States | Recruiting |
| Oncology Hematology Care, Inc - Blue Ash /ID# 262733 | Cincinnati, Ohio, United States | Recruiting |
+ 49 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06236438